Pliant Therapeutics Inc (PLRX)

06:01 AM

Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024 - GlobeNewswire

06:01 AM

06:00 AM

Pliant's Bexotegrast Shows Strong Phase 2 Results in Liver Disease Treatment Trial | PLRX Stock News - StockTitan

06:00 AM

Nov 15, 2024

Redmile Group, LLC Adjusts Stake in Pliant Therapeutics Inc - GuruFocus.com

Nov 15, 2024

Nov 15, 2024

First Light Asset Management's Strategic Reduction in Pliant The - GuruFocus.com

Nov 15, 2024

Nov 08, 2024

HC Wainwright Reiterates "Buy" Rating for Pliant Therapeutics (NASDAQ:PLRX) - MarketBeat

Nov 08, 2024

Nov 07, 2024

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - The Manila Times

Nov 07, 2024

Nov 07, 2024

Pliant Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 07, 2024

Nov 07, 2024

Possible Bearish Signals With Pliant Therapeutics Insiders Disposing Stock - Simply Wall St

Nov 07, 2024

Nov 07, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Acquired by Harbor Capital Advisors Inc. - MarketBeat

Nov 07, 2024

Nov 06, 2024

Pliant Therapeutics to Participate in the Stifel Healthcare Conference - The Manila Times

Nov 06, 2024

Nov 06, 2024

Pliant Therapeutics to Present at Stifel 2024 Healthcare Conference | Key Leadership Insights | PLRX Stock News - StockTitan

Nov 06, 2024

Nov 03, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of “Buy” by Analysts - Defense World

Nov 03, 2024

Nov 03, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

Nov 03, 2024

Oct 21, 2024

Pliant Therapeutics (NASDAQ:PLRX) Stock Price Down 5.4%Time to Sell? - MarketBeat

Oct 21, 2024

Oct 21, 2024

SG Americas Securities LLC Decreases Stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World

Oct 21, 2024

Oct 17, 2024

Pliant reports positive Phase 2a trial results for liver disease drug - Investing.com Australia

Oct 17, 2024

Oct 17, 2024

Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating - GlobeNewswire

Oct 17, 2024

Oct 17, 2024

Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024 - Yahoo Finance

Oct 17, 2024

Oct 15, 2024

Pliant Therapeutics Inc (PLRX)’s stock price in review: A technical analysis - US Post News

Oct 15, 2024

Oct 14, 2024

Pliant Therapeutics Inc’s Mixed Bag: Down -3.53% in 6 Months, Down 15.29% in 30 Days - The InvestChronicle

Oct 14, 2024

Oct 14, 2024

An Analysis of Pliant Therapeutics Inc (PLRX)’s Potential Price Growth - Knox Daily

Oct 14, 2024

Oct 14, 2024

The Manufacturers Life Insurance Company Purchases 1,191 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World

Oct 14, 2024

Oct 13, 2024

How To Trade (PLRX) - Stock Traders Daily

Oct 13, 2024

Oct 09, 2024

Pliant Therapeutics (NASDAQ:PLRX) Trading 4.5% HigherStill a Buy? - MarketBeat

Oct 09, 2024

Oct 09, 2024

Pliant Therapeutics Inc [PLRX] Stock sold by Insider Lefebvre Eric for $0.14 million - Knox Daily

Oct 09, 2024

Oct 09, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of "Buy" by Analysts - MarketBeat

Oct 09, 2024

Oct 07, 2024

Squarepoint Ops LLC Takes $865,000 Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - MarketBeat

Oct 07, 2024

Oct 06, 2024

Algert Global LLC Increases Stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - MarketBeat

Oct 06, 2024

Oct 04, 2024

Paradigm Biocapital Advisors LP Acquires New Stake in Pliant Therapeutics Inc - Yahoo Finance

Oct 04, 2024

Oct 02, 2024

Pliant Therapeutics stock hits 52-week low at $10.24 - Investing.com

Oct 02, 2024

Oct 02, 2024

Pliant Therapeutics appoints new SVP of Medical Affairs - Investing.com India

Oct 02, 2024

Oct 02, 2024

Pliant Therapeutics stock hits 52-week low at $10.24 By Investing.com - Investing.com Australia

Oct 02, 2024

Oct 02, 2024

Pliant Therapeutics (NASDAQ:PLRX) Sets New 12-Month Low at $10.24 - MarketBeat

Oct 02, 2024

Oct 02, 2024

Pliant Therapeutics (NASDAQ:PLRX) Hits New 1-Year Low at $10.24 - Defense World

Oct 02, 2024

Oct 02, 2024

Investor’s Toolkit: Key Ratios for Assessing Pliant Therapeutics Inc (PLRX)’s Performance - The Dwinnex

Oct 02, 2024

Oct 02, 2024

American Century Companies Inc. Has $797,000 Stock Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World

Oct 02, 2024

Oct 01, 2024

Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs - GlobeNewswire

Oct 01, 2024

Oct 01, 2024

Lululemon Athletica (LULU-Q) QuotePress Release - The Globe and Mail

Oct 01, 2024

Oct 01, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Acquired by Renaissance Technologies LLC - Defense World

Oct 01, 2024

Sep 30, 2024

Ensign Peak Advisors Inc Grows Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World

Sep 30, 2024

Sep 30, 2024

Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Bakersfield Californian

Sep 30, 2024

Sep 30, 2024

11,678 Shares in Pliant Therapeutics, Inc. (NASDAQ:PLRX) Acquired by Deerfield Management Company L.P. Series C - Defense World

Sep 30, 2024

Sep 28, 2024

Pliant Therapeutics updates bylaws, aligns with Delaware law By Investing.com - Investing.com South Africa

Sep 28, 2024

Sep 27, 2024

Pliant Therapeutics updates bylaws, aligns with Delaware law - Investing.com

Sep 27, 2024

Sep 25, 2024

Investing in Pliant Therapeutics Inc (PLRX) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News

Sep 25, 2024

Sep 25, 2024

Pliant Therapeutics Inc (PLRX) receives an Outperform rating from Leerink Partners - Knox Daily

Sep 25, 2024

Sep 25, 2024

Pharma stock to buy now for an upside of 20%; Are you holding it? - Trade Brains

Sep 25, 2024